[go: up one dir, main page]

PE20140966A1 - Quinazolincarboxamida azetidinas - Google Patents

Quinazolincarboxamida azetidinas

Info

Publication number
PE20140966A1
PE20140966A1 PE2013001281A PE2013001281A PE20140966A1 PE 20140966 A1 PE20140966 A1 PE 20140966A1 PE 2013001281 A PE2013001281 A PE 2013001281A PE 2013001281 A PE2013001281 A PE 2013001281A PE 20140966 A1 PE20140966 A1 PE 20140966A1
Authority
PE
Peru
Prior art keywords
quinazoline
azethydines
hal
ethylamine
carboxyl
Prior art date
Application number
PE2013001281A
Other languages
English (en)
Inventor
Bayard R Huck
Reinaldo Jones
Yufang Xiao
Constantin Neagu
Donald Bankston
Andreas Goutopoulos
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20140966A1 publication Critical patent/PE20140966A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE AUN COMPUESTO DE FORMULA (I) Y SUS ESTEREOISOMEROS, TAUTOMEROS, ENTRE OTROS, EN DONDE: R1 ES H; R2 ES HAL, AR, CONH2, ENTRE OTROS; R3', R3", SON H, LA O HAL; AR ES UN HETEROCICLO AROMATICO MONO, BICICLICO QUE TIENE 0, 1, 2, 3, 4 ATOMOS DE N, O ENTRE OTROS. SON COMPUESTOS PREFERIDOS AMIDA DEL ACIDO 4-[(S)-2-AZETIDIN-1-IL-1-(3-FLUOROFENIL)-ETILAMINO]-QUINAZOLIN-8-CARBOXILICO; AMIDA DEL ACIDO 4-[(S)-2-AZETIDIN-1-IL-1-(3-CLOROFENIL)-ETILAMINO]-QUINAZOLIN-8-CARBOXILICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, SIENDO UTIL PARA EL TRATAMINETO DE ENFERMEDADES HIPERPROLIFERATIVAS
PE2013001281A 2010-11-24 2011-11-11 Quinazolincarboxamida azetidinas PE20140966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41713110P 2010-11-24 2010-11-24

Publications (1)

Publication Number Publication Date
PE20140966A1 true PE20140966A1 (es) 2014-08-06

Family

ID=45001695

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001281A PE20140966A1 (es) 2010-11-24 2011-11-11 Quinazolincarboxamida azetidinas

Country Status (30)

Country Link
US (1) US8946247B2 (es)
EP (1) EP2643313B9 (es)
JP (1) JP5897590B2 (es)
KR (1) KR101894116B1 (es)
CN (1) CN103228649B (es)
AR (1) AR093725A1 (es)
AU (1) AU2011334173B2 (es)
BR (1) BR112013012488B1 (es)
CA (1) CA2818706C (es)
CL (1) CL2013001459A1 (es)
CO (1) CO6721019A2 (es)
DK (1) DK2643313T3 (es)
EA (1) EA023821B1 (es)
ES (1) ES2594404T3 (es)
HR (1) HRP20161183T1 (es)
HU (1) HUE028967T2 (es)
IL (1) IL226233A (es)
LT (1) LT2643313T (es)
MX (1) MX355325B (es)
MY (1) MY186456A (es)
NZ (1) NZ612224A (es)
PE (1) PE20140966A1 (es)
PL (1) PL2643313T3 (es)
PT (1) PT2643313T (es)
RS (1) RS55204B1 (es)
SG (1) SG190318A1 (es)
SI (1) SI2643313T1 (es)
UA (1) UA112167C2 (es)
WO (1) WO2012069146A1 (es)
ZA (1) ZA201304637B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014005468A2 (pt) 2011-09-12 2017-03-21 Merck Patent Gmbh derivados de aminopiridina para uso como moduladores de atividade quinase
LT2755965T (lt) 2011-09-12 2017-11-10 Merck Patent Gmbh Naujieji imidazolo aminai kaip kinazės aktyvumo moduliatoriai
ES2656096T3 (es) 2012-11-16 2018-02-23 Merck Patent Gmbh Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
AU2013344552B2 (en) 2012-11-16 2018-03-15 Xiaoling Chen Novel heterocyclic derivatives as modulators of kinase activity
EP2925747B1 (en) * 2012-11-29 2020-06-24 Merck Patent GmbH Azaquinazoline carboxamide derivatives
KR20150124957A (ko) 2013-03-11 2015-11-06 메르크 파텐트 게엠베하 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체
KR102410696B1 (ko) 2014-04-03 2022-06-17 메르크 파텐트 게엠베하 암 치료법의 조합
CA2970394C (en) * 2014-12-11 2023-03-14 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
WO2017140793A1 (en) * 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
EP3416640A1 (en) * 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP4243819A1 (en) 2020-11-16 2023-09-20 Merck Patent GmbH Kinase inhibitor combinations for cancer treatment
CN116490187A (zh) * 2020-11-16 2023-07-25 默克专利股份公司 用于癌症治疗的激酶抑制剂组合
US11866421B2 (en) * 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
KR20250068623A (ko) 2022-08-11 2025-05-16 이벡스타 바이오 암 치료용 화합물
WO2025168601A1 (en) * 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JPWO2004014873A1 (ja) * 2002-08-09 2005-12-02 杏林製薬株式会社 4−置換キナゾリン−8−カルボン酸アミド誘導体とその薬理上許容される付加塩
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004230841A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2004278413B2 (en) 2003-09-30 2008-07-31 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2004283751B2 (en) 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
AU2004296868B2 (en) 2003-12-09 2010-11-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for suppressing an immune response or treating a proliferative disorder
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
PL2396307T3 (pl) * 2009-02-11 2015-03-31 Merck Patent Gmbh Nowe aminowe azaheterocykliczne karboksyamidy
BR112013002212A2 (pt) * 2010-07-29 2017-09-26 Merck Patent Gmbh carboxamidas aza-heterocíclicas de aminas cíclicas
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди

Also Published As

Publication number Publication date
AR093725A1 (es) 2015-06-24
HUE028967T2 (en) 2017-01-30
ZA201304637B (en) 2014-03-26
US20130252942A1 (en) 2013-09-26
IL226233A (en) 2017-07-31
SI2643313T1 (sl) 2016-11-30
CA2818706C (en) 2019-07-23
ES2594404T3 (es) 2016-12-20
JP5897590B2 (ja) 2016-03-30
AU2011334173A1 (en) 2013-05-02
EA023821B1 (ru) 2016-07-29
PL2643313T3 (pl) 2017-03-31
EP2643313B9 (en) 2017-02-22
CN103228649B (zh) 2015-11-25
JP2013544257A (ja) 2013-12-12
MY186456A (en) 2021-07-22
PT2643313T (pt) 2016-10-11
RS55204B1 (sr) 2017-01-31
BR112013012488A2 (pt) 2016-07-19
HK1188444A1 (zh) 2014-05-02
MX355325B (es) 2018-04-16
AU2011334173B2 (en) 2015-07-16
IL226233A0 (en) 2013-07-31
WO2012069146A1 (en) 2012-05-31
DK2643313T3 (en) 2016-10-24
EA201300610A1 (ru) 2013-12-30
HRP20161183T1 (hr) 2016-11-04
NZ612224A (en) 2015-01-30
CA2818706A1 (en) 2012-05-31
KR20130130753A (ko) 2013-12-02
BR112013012488B1 (pt) 2021-08-31
LT2643313T (lt) 2016-10-25
EP2643313A1 (en) 2013-10-02
US8946247B2 (en) 2015-02-03
SG190318A1 (en) 2013-06-28
UA112167C2 (uk) 2016-08-10
EP2643313B1 (en) 2016-06-29
MX2013005751A (es) 2013-08-01
CN103228649A (zh) 2013-07-31
CL2013001459A1 (es) 2013-12-27
CO6721019A2 (es) 2013-07-31
KR101894116B1 (ko) 2018-08-31

Similar Documents

Publication Publication Date Title
PE20140966A1 (es) Quinazolincarboxamida azetidinas
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
PE20091843A1 (es) Inhibidores de catepsina c
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
DK2840080T3 (da) Nitrogenholdig heterocyklisk forbindelse eller salt deraf
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX369508B (es) Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
IN2012DN02502A (es)
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
UA103329C2 (ru) Соли соединений-ингибиторов вич
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
CO6710902A2 (es) Inhibidores de oxadiazol de la producción de leucotrienos
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
EA201300092A1 (ru) Замещенные производные оксадиазола

Legal Events

Date Code Title Description
FG Grant, registration